#USA #New York #Class Action #Pomerantz LLP #Hims & Hers

Investor Alert: Hims & Hers Health, Inc. Under Class Action

In a significant development for investors, Pomerantz LLP has announced a class action lawsuit against Hims & Hers Health, Inc. This action stems from allegations of securities fraud and questionable business practices. Investors who suffered losses due to their investment in Hims & Hers are encouraged to respond before the upcoming deadline of August 25, 2025.

Context of the Lawsuit

On April 29, 2025, Hims & Hers announced a collaboration with Novo Nordisk to sell its FDA-approved medication, Wegovy®, through their platform. This partnership marked a promising expansion for the company. However, a drastic turn of events occurred on June 23, 2025, when Novo Nordisk decided to terminate their partnership with Hims & Hers due to allegations of deceptive practices. The press release from Novo Nordisk accused Hims & Hers of misrepresenting and selling illegitimate versions of Wegovy®, raising significant safety concerns for patients.

According to the announcement, Hims & Hers allegedly promoted compounded drugs without adhering to legal standards, thus risking patient safety. Novo Nordisk claimed that the active pharmaceutical ingredients used in the unapproved drugs were sourced from questionable foreign suppliers, casting doubt on their safety and efficacy in the U.S. market.

Impact on Investors

Following this shocking news, Hims & Hers experienced a considerable drop in their stock price, plummeting by 34.63% to close at $41.98 a share on the day of the announcement. This dramatic decline raised alarms among investors, particularly those who acquired shares during the tumultuous period.

Pomerantz LLP, known for its expertise in corporate and securities litigation, urges affected investors to take immediate action. Those who purchased Hims & Hers securities during the class period can reach out to the firm to discuss potentially becoming a Lead Plaintiff in the ongoing lawsuit. The legal team encourages investors to contact Danielle Peyton, providing relevant details such as their mailing address and number of shares purchased.

How to Join the Lawsuit

If you are an investor impacted by these events, you have until August 25, 2025, to express your interest in joining this legal action. The lawsuit could offer a potential avenue for recourse against the alleged securities fraud and provide a voice for those affected by Hims & Hers' purported misconduct. Through this legal mechanism, Pomerantz LLP seeks to hold the company accountable and advocate for the rights of defrauded investors.

For additional information or to join the class action, investors are advised to visit Pomerantz LLP's official website or contact them directly. Navigating the complexities of class actions can be daunting; however, the firm assures aggressive representation for its clients, aiming to recover losses from corporate misconduct.

This ongoing case serves as a crucial reminder for investors to exercise diligence and vigilance in their investment decisions, particularly in the healthcare sector where regulatory compliance is paramount. Investors are encouraged to stay informed about their rights and the developments of this unfolding legal saga.